Ifosfamide in refractory male germ cell tumors

B. M. Wheeler, Patrick Loehrer, S. D. Williams, Lawrence Einhorn

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

We conducted a phase II clinical trial using ifosfamide (IFX) as a single agent in cisplatin-refractory male germ cell tumor. Thirty patients with measurable disease were treated with IFX, 2 g/m2 intravenously (IV) for 5 consecutive days every 3 weeks. N-acetylcysteine, 2 g orally every 4 hours, was given as a uroprotective agent. All patients had previously been treated with cisplatin, vinblastine, and bleomycin, and all except two also had previously received etoposide. There were six partial responses (PR) and one complete response (CR) for an overall objective response rate of 23%. The median duration of response was 3.5 months (range, 2 to 5.5 months). The median survival time was 3.5 months (range, 2 to 14+ months). The toxicity of the regimen consisted of hematuria (65% of the patients), nausea and vomiting (43%), neutropenia (WBC < 2,000; 52%), thrombocytopenia (platelet count < 50,000; 20%), and nephrotoxicity (12%). Hematuria was dose related, occurring in 48% of courses using 2 g/m2 v only 5% of courses at lower doses. Serious nephrotoxicity (creatinine level > 6.0 mg/mL) was observed in three patients with an elevated pretreatment serum creatinine level. In conclusion, IFX is an active agent in this heavily pretreated population with advanced refractory germ cell tumor.

Original languageEnglish
Pages (from-to)28-34
Number of pages7
JournalJournal of Clinical Oncology
Volume4
Issue number1
StatePublished - 1986

Fingerprint

Ifosfamide
Cisplatin
Phase II Clinical Trials
Vinblastine
Germ Cell and Embryonal Neoplasms
Bleomycin
Acetylcysteine
Hematuria
Etoposide
Neutropenia
Nausea
Vomiting
Creatinine
Survival
Male Germ Cell Tumor
Serum
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ifosfamide in refractory male germ cell tumors. / Wheeler, B. M.; Loehrer, Patrick; Williams, S. D.; Einhorn, Lawrence.

In: Journal of Clinical Oncology, Vol. 4, No. 1, 1986, p. 28-34.

Research output: Contribution to journalArticle

Wheeler, B. M. ; Loehrer, Patrick ; Williams, S. D. ; Einhorn, Lawrence. / Ifosfamide in refractory male germ cell tumors. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 1. pp. 28-34.
@article{4a474c1caebd4625a9efe3db9da68f04,
title = "Ifosfamide in refractory male germ cell tumors",
abstract = "We conducted a phase II clinical trial using ifosfamide (IFX) as a single agent in cisplatin-refractory male germ cell tumor. Thirty patients with measurable disease were treated with IFX, 2 g/m2 intravenously (IV) for 5 consecutive days every 3 weeks. N-acetylcysteine, 2 g orally every 4 hours, was given as a uroprotective agent. All patients had previously been treated with cisplatin, vinblastine, and bleomycin, and all except two also had previously received etoposide. There were six partial responses (PR) and one complete response (CR) for an overall objective response rate of 23{\%}. The median duration of response was 3.5 months (range, 2 to 5.5 months). The median survival time was 3.5 months (range, 2 to 14+ months). The toxicity of the regimen consisted of hematuria (65{\%} of the patients), nausea and vomiting (43{\%}), neutropenia (WBC < 2,000; 52{\%}), thrombocytopenia (platelet count < 50,000; 20{\%}), and nephrotoxicity (12{\%}). Hematuria was dose related, occurring in 48{\%} of courses using 2 g/m2 v only 5{\%} of courses at lower doses. Serious nephrotoxicity (creatinine level > 6.0 mg/mL) was observed in three patients with an elevated pretreatment serum creatinine level. In conclusion, IFX is an active agent in this heavily pretreated population with advanced refractory germ cell tumor.",
author = "Wheeler, {B. M.} and Patrick Loehrer and Williams, {S. D.} and Lawrence Einhorn",
year = "1986",
language = "English",
volume = "4",
pages = "28--34",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Ifosfamide in refractory male germ cell tumors

AU - Wheeler, B. M.

AU - Loehrer, Patrick

AU - Williams, S. D.

AU - Einhorn, Lawrence

PY - 1986

Y1 - 1986

N2 - We conducted a phase II clinical trial using ifosfamide (IFX) as a single agent in cisplatin-refractory male germ cell tumor. Thirty patients with measurable disease were treated with IFX, 2 g/m2 intravenously (IV) for 5 consecutive days every 3 weeks. N-acetylcysteine, 2 g orally every 4 hours, was given as a uroprotective agent. All patients had previously been treated with cisplatin, vinblastine, and bleomycin, and all except two also had previously received etoposide. There were six partial responses (PR) and one complete response (CR) for an overall objective response rate of 23%. The median duration of response was 3.5 months (range, 2 to 5.5 months). The median survival time was 3.5 months (range, 2 to 14+ months). The toxicity of the regimen consisted of hematuria (65% of the patients), nausea and vomiting (43%), neutropenia (WBC < 2,000; 52%), thrombocytopenia (platelet count < 50,000; 20%), and nephrotoxicity (12%). Hematuria was dose related, occurring in 48% of courses using 2 g/m2 v only 5% of courses at lower doses. Serious nephrotoxicity (creatinine level > 6.0 mg/mL) was observed in three patients with an elevated pretreatment serum creatinine level. In conclusion, IFX is an active agent in this heavily pretreated population with advanced refractory germ cell tumor.

AB - We conducted a phase II clinical trial using ifosfamide (IFX) as a single agent in cisplatin-refractory male germ cell tumor. Thirty patients with measurable disease were treated with IFX, 2 g/m2 intravenously (IV) for 5 consecutive days every 3 weeks. N-acetylcysteine, 2 g orally every 4 hours, was given as a uroprotective agent. All patients had previously been treated with cisplatin, vinblastine, and bleomycin, and all except two also had previously received etoposide. There were six partial responses (PR) and one complete response (CR) for an overall objective response rate of 23%. The median duration of response was 3.5 months (range, 2 to 5.5 months). The median survival time was 3.5 months (range, 2 to 14+ months). The toxicity of the regimen consisted of hematuria (65% of the patients), nausea and vomiting (43%), neutropenia (WBC < 2,000; 52%), thrombocytopenia (platelet count < 50,000; 20%), and nephrotoxicity (12%). Hematuria was dose related, occurring in 48% of courses using 2 g/m2 v only 5% of courses at lower doses. Serious nephrotoxicity (creatinine level > 6.0 mg/mL) was observed in three patients with an elevated pretreatment serum creatinine level. In conclusion, IFX is an active agent in this heavily pretreated population with advanced refractory germ cell tumor.

UR - http://www.scopus.com/inward/record.url?scp=0022642509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022642509&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 28

EP - 34

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -